Abstract:The heart possesses a remarkable inherent capability to adapt itself to a wide array of genetic and extrinsic factors to maintain contractile function. Failure to sustain its compensatory responses results in cardiac dysfunction, leading to cardiomyopathy. Diabetic cardiomyopathy (DCM) is characterized by left ventricular hypertrophy and reduced diastolic function, with or without concurrent systolic dysfunction in the absence of hypertension and coronary artery disease. Changes in substrate metabolism, oxidative stress, endoplasmic reticulum stress, formation of extracellular matrix proteins, and advanced glycation end products constitute the early stage in DCM. These early events are followed by steatosis (accumulation of lipid droplets) in cardiomyocytes, which is followed by apoptosis, changes in immune responses with a consequent increase in fibrosis, remodeling of cardiomyocytes, and the resultant decrease in cardiac function. The heart is an omnivore, metabolically flexible, and consumes the highest amount of ATP in the body. Altered myocardial substrate and energy metabolism initiate the development of DCM. Diabetic hearts shift away from the utilization of glucose, rely almost completely on fatty acids (FAs) as the energy source, and become metabolically inflexible. Oxidation of FAs is metabolically inefficient as it consumes more energy. In addition to metabolic inflexibility and energy inefficiency, the diabetic heart suffers from impaired calcium handling with consequent alteration of relaxation-contraction dynamics leading to diastolic and systolic dysfunction. Sarcoplasmic reticulum (SR) plays a key role in excitation-contraction coupling as Ca2+ is transported into the SR by the SERCA2a (sarcoplasmic/endoplasmic reticulum calcium-ATPase 2a) during cardiac relaxation. Diabetic cardiomyocytes display decreased SERCA2a activity and leaky Ca2+ release channel resulting in reduced SR calcium load. The diabetic heart also suffers from marked downregulation of novel cardioprotective microRNAs (miRNAs) discovered recently. Since immune responses and substrate energy metabolism are critically altered in diabetes, the present review will focus on immunometabolism and miRNAs.

Role of the Cathepsin K/Calcineurin/Nuclear Factor of Activated T-cells Axis in the Pathogenesis and Management of Diabetic Cardiomyopathy

Calcium Homeostasis in Ventricular Myocytes of Diabetic Cardiomyopathy

Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence

Cathepsin K knockout protects against cardiac dysfunction in diabetic mice

Diabetic cardiomyopathy: role of the E3 ubiquitin ligase.

Impaired SERCA2a Phosphorylation Causes Diabetic Cardiomyopathy Through Impinging on Cardiac Contractility and Precursor Protein Processing

Pathophysiological Fundamentals of Diabetic Cardiomyopathy.

Application of Animal Models in Diabetic Cardiomyopathy

The interplay of inflammation, exosomes and Ca2+ dynamics in diabetic cardiomyopathy

Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy

Understanding diabetes-induced cardiomyopathy from the perspective of renin angiotensin aldosterone system

Diabetic Cardiomyopathy: An Immunometabolic Perspective

Myocardial protection of S-nitroso-L-cysteine in diabetic cardiomyopathy mice

The role of NF-κB in diabetic cardiomyopathy

Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy

Myocardial redox status, mitophagy and cardioprotection: a potential way to amend diabetic heart?

Diabetic Cardiomyopathy: from Mechanism to Management in a Nutshell.

Targeting Autophagy in Diabetic Cardiomyopathy: from Molecular Mechanisms to Pharmacotherapy

Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions

The Importance of Caveolin As a Target in the Prevention and Treatment of Diabetic Cardiomyopathy

Novel Insights Into the Pathogenesis of Diabetic Cardiomyopathy and Pharmacological Strategies